Changshan Biochemical Pharmaceutical’s capacity of low molecular weight heparin calcium injection will expand to 20 mln annually

Date:2011-09-13     Source:liaoyanhangmei  Text Size:

Changshan Biochemical Pharmaceutical (hereafter referred as CSBIO) was listed in Shenzhen Stock Exchange on 19 Aug. 2011, with registered capital of RMB110 million. Heparin Sodium BPC is the core product of CSBIO, of which market share ranks first in China. Its sales reached RMB410 million in 2010, accounting for 86.9% of CSBIO’s operating revenue. Through going public, CSBIO will expand its heparin sodium BPC capacity and realize an annual capacity of 3 trillion units.

For low molecular weight heparin calcium injection, CSBIO is one of the six enterprises that obtain production approval in China. Its market share topped the industry in China in 2009. When the fund-raise project reaches designed capacity, LMW heparin calcium injection capacity will be expanded from 4 million units to 20 million units, consequently, its sales will increase from RMB50 million in 2010 to be over RMB200 million.

 

Fund Raising Projects and Investment of Changshan Biochemical Pharmaceutical

 

No.

Project

Total Investment (RMB mln)

1

Refined heparin BPC capacity expansion project (3 trillion units/year )

267.9

2

LMW heparin injection capacity expansion project (20 mln units/ year)

118.0

3

LMW heparin BPC R&D and industrialization project (2,000 kg/year)

114.1

4

Construction project of R&D center

26.3

 Source: Changshan Biochemical Pharmaceutical; ResearchInChina

 

2005-2011 www.researchinchina.com All Rights Reserved 京ICP备05069564号-1